204 related articles for article (PubMed ID: 8967957)
21. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
22. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.
Lidonnici MR; Corradini F; Waldron T; Bender TP; Calabretta B
Blood; 2008 May; 111(9):4771-9. PubMed ID: 18227349
[TBL] [Abstract][Full Text] [Related]
23. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
24. Raf-1 protein is required for growth factor-induced proliferation of primitive hematopoietic progenitors stimulated with synergistic combinations of cytokines.
Muszynski KW; Ruscetti FW; Gooya JM; Linnekin DM; Keller JR
Stem Cells; 1997; 15(1):63-72. PubMed ID: 9007224
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
Gewirtz AM
Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
[No Abstract] [Full Text] [Related]
26. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
[TBL] [Abstract][Full Text] [Related]
27. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides.
Skorski T; Szczylik C; Ratajczak MZ; Malaguarnera L; Gewirtz AM; Calabretta B
J Exp Med; 1992 Mar; 175(3):743-50. PubMed ID: 1371302
[TBL] [Abstract][Full Text] [Related]
28. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Svingen PA; Tefferi A; Kottke TJ; Kaur G; Narayanan VL; Sausville EA; Kaufmann SH
Clin Cancer Res; 2000 Jan; 6(1):237-49. PubMed ID: 10656455
[TBL] [Abstract][Full Text] [Related]
29. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
30. Down-regulated c-myb expression inhibits DNA synthesis of T-leukemia cells in most patients.
Venturelli D; Mariano MT; Szczylik C; Valtieri M; Lange B; Crist W; Link M; Calabretta B
Cancer Res; 1990 Nov; 50(22):7371-5. PubMed ID: 2224864
[TBL] [Abstract][Full Text] [Related]
31. Lineage-specific requirement of c-abl function in normal hematopoiesis.
Caracciolo D; Valtieri M; Venturelli D; Peschle C; Gewirtz AM; Calabretta B
Science; 1989 Sep; 245(4922):1107-10. PubMed ID: 2672339
[TBL] [Abstract][Full Text] [Related]
32. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
33. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
34. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
35. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
[TBL] [Abstract][Full Text] [Related]
36. Effects of the antisense v-myb' expression on K562 human leukemia cell proliferation and differentiation.
Kamano H; Ohnishi H; Tanaka T; Ikeda K; Okabe A; Irino S
Leuk Res; 1990; 14(10):831-9. PubMed ID: 1979645
[TBL] [Abstract][Full Text] [Related]
37. Antisense myb inhibition of purified erythroid progenitors in development and differentiation is linked to cycling activity and expression of DNA polymerase alpha.
Valtieri M; Venturelli D; Caré A; Fossati C; Pelosi E; Labbaye C; Mattia G; Gewirtz AM; Calabretta B; Peschle C
Blood; 1991 Mar; 77(6):1181-90. PubMed ID: 1705831
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
39. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
40. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
